Business Wire

CA-ATTACKIQ

20.4.2022 15:02:05 CEST | Business Wire | Press release

Share
AttackIQ Announces Integration with Vectra AI Threat Detection and Response Platform to Help Customers Optimize their Security Control Effectiveness

AttackIQ ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced a new integration with Vectra®, an AI-driven threat detection and response platform that enables joint customers to detect attacks that have bypassed existing security controls and ensure rapid response to the latest threats.

"In today's hyper-complex threat environment, organizations must think proactively and adopt advanced security capabilities to prevent successful attacks," said Carl Wright, Chief Commercial Officer at AttackIQ. "This integration will allow our customers to validate the efficacy of the Vectra AI platform by utilizing AttackIQ's PCAP replay and related network scenarios to find and fix coverage gaps throughout their security infrastructure before adversaries exploit them."

AttackIQ operates under the "assume breach" mindset, recognizing that it is not a question of if but when an intruder will break past an organization's perimeter defense. Leveraging automated breach and attack simulation technology and the MITRE ATT&CK framework, the AttackIQ Security Optimization Platform enables organizations to measure their security controls performance, identify misconfigurations or gaps in coverage, and focus resources on areas with the highest probability of risk exposure.

"It is exciting to see AttackIQ and Vectra joining forces to help customers enable a proactive, threat-informed defense," said Geert Busse, Head of Next-Gen Solutions Pre Sales EMEA, Westcon. "As key vendors in our Westcon Next Generation Solutions go-to-market strategy, these two organizations are the backbone of our technology pillar, focusing on defense against emerging threats by delivering automation, integration and efficiency that our industry needs to detect and stop the latest generation of Threat Actors."

The Vectra Platform uses security-led artificial intelligence (AI) to power threat detection and response to ensure speed, precision, and efficiency in surfacing and stopping attacks before devastating impact. The platform captures data from network packets and logs that give insight into companies' public cloud and SaaS environment, federated identity, and data center networks. Vectra's patented approach to applying AI to detection analyzes all detection to prioritize threats and map events to MITRE ATT&CK framework without noise and hunting. It further drives appropriate remediation and rapid response through other tools already implemented in your security stack.

The AttackIQ Security Optimization Platform integration with the Vectra Threat Detection and Response Platform is available today.

To learn more about this integration and see it in action register for the May 5th demo here: https://attackiq.com/get-a-demo/weekly-demo/ .

About AttackIQ

AttackIQ, the leading independent vendor of breach and attack simulation solutions, built the industry's first Security Optimization Platform for continuous security control validation and improving security program effectiveness and efficiency. AttackIQ is trusted by leading organizations worldwide to plan security improvements and verify that cyberdefenses work as expected, aligned with the MITRE ATT&CK framework. The Company is committed to giving back to the cybersecurity community through its free award-winning AttackIQ Academy , open Preactive Security Exchange, and partnership with MITRE Engenuity's Center for Threat-Informed Defense . For more information, visit www.attackiq.com . Follow AttackIQ on Twitter , Facebook , LinkedIn , and YouTube .

About Vectra AI

Vectra® is a leader in threat detection and response for hybrid and multi-cloud enterprises. The Vectra platform uses AI to detect threats at speed across public cloud, identity, SaaS applications, and data centers. Only Vectra optimizes AI to detect attacker methods—the TTPs at the heart of all attacks—rather than simplistically alerting on "different". The resulting high-fidelity threat signal and clear context enables security teams to respond to threats sooner and to stop attacks in progress faster. Organizations worldwide rely on Vectra for cybersecurity resilience in the face of dangerous cyber threats and to prevent ransomware, supply chain compromise, identity takeovers, and other cyberattacks from impacting their businesses. For more information, visit vectra.ai.

Link:

ClickThru

Social Media:

https://www.facebook.com/AttackIQ/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye